Techlicious

Review of the Quell 2.0 Wearable Pain Relief Device

New design and features of Quell 2.0 NeuroMetrix focused largely on two things to differentiate version 2.0: make the device smaller, and more functional with the mobile app for iOS and Android. The ...
CNN

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes direct ...
Nasdaq

electroCore, Inc. Announces Acquisition of NeuroMetrix, Inc. to Enhance Bioelectronic Health and Wellness Offerings with Quell® Platform

electroCore, Inc. announced its agreement to acquire NeuroMetrix, Inc., which will enhance its role in the bioelectronic health and wellness market by adding NeuroMetrix's Quell platform, a ...
Nasdaq

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve ...
Techlicious

Review of the Quell 2.0 Wearable Pain Relief Device

The Quell 2.0 can’t assess or measure pain, so it needs you to do it, selecting from 0-10 the level of pain you felt generally, when active, while sleeping and how it affected your mood. Using those ...